Perioperative chemotherapy of stage Ⅲ N2 non-small cell lung cancer by Shun LU, Yongfeng YU

Get full text

Treatment-related Skin Toxicity Caused by Programmed Death-1 Inhibitor Nivolumab: 
A Case Report by Lin GAO, Yongfeng YU, Shun LU

Get full text

Comparison of Efficacy and Safety of Brigatinib in First-Line Treatments for Patients with Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Systematic Review and I... by Yongfeng Yu, Fanfan Zhu, Wenxin Zhang, Shun Lu

Get full text

Cost-effectiveness of ALK testing and first-line crizotinib therapy for non-small-cell lung cancer in China. by Shun Lu, Yongfeng Yu, Shijun Fu, Hongye Ren

Get full text

Comprehensive Molecular Characterizations of Chinese Patients With Different Subtypes of Lung Squamous Cell Carcinoma by Jie Qian, Rongrong Chen, Ruiying Zhao, Yuchen Han, Yongfeng Yu

Get full text

Immunotherapy strategies for EGFR-mutated advanced NSCLC after EGFR tyrosine-kinase inhibitors failure by Xingyuan Li, Huayan Huang, Yingjia Sun, Qing Jiang, Yongfeng Yu

Get full text

Comprehensive molecular characterizations of stage I–III lung adenocarcinoma with tumor spread through air spaces by Ronghao Ye, Yongfeng Yu, Ruiying Zhao, Yuchen Han, Shun Lu

Get full text

Chinese multidisciplinary expert consensus on the management of adverse drug reactions associated with savolitinib by Li Zhang, Yongsheng Wang, Lizhu Lin, Yongfeng Yu, Shun Lu

Get full text

Gemcitabine Combined with Vinorelbine in the Treatment of Refractory Patients with Advanced Non-small Cell Lung Cancer: A Multi-center Retrospective Study by Shun LU, Li ZHANG, Yongfeng YU, Gongyan CHEN, Qing ZHAO

Get full text

Efficacy of Gemcitabine and Vinorelbine in First-line Treatment 
with Advanced Non-small Cell Lung Cancer: A Multicentre Retrospective Study by Yongfeng YU, Li ZHANG, Zhisheng REN, Jiujun ZHAO, Zhongrui LI, Shun LU

Get full text

Treatment strategies based on different oligoprogressive patterns after immunotherapy failure in metastatic NSCLC by Wendi Xuzhang, Huayan Huang, Yongfeng Yu, Lan Shen, Ziming Li, Shun Lu

Get full text

SMO mutation predicts the effect of immune checkpoint inhibitor: From NSCLC to multiple cancers by Wenxiang Ji, Xiaomin Niu, Yongfeng Yu, Ziming Li, LinPing Gu, Shun Lu

Get full text

Antimicrobial Resistance Surveillance of Tigecycline-Resistant Strains Isolated from Herbivores in Northwest China by Yongfeng Yu, Changchun Shao, Xiaowei Gong, Heng Quan, Donghui Liu, Qiwei Chen, Yuefeng Chu

Get full text

Landscape and Predictive Significance of the Structural Classification of <i>EGFR</i> Mutations in Chinese NSCLCs: A Real-World Study by Linping Gu, Huayan Huang, Zhangwendi Xu, Xiaomin Niu, Ziming Li, Liliang Xia, Yongfeng Yu, Shun Lu

Get full text

Pyrotinib combined with thalidomide in advanced non-small-cell lung cancer patients harboring HER2 exon 20 insertions (PRIDE): protocol of an open-label, single-arm phase II trial by Xinghao Ai, Zhengbo Song, Hong Jian, Zhen Zhou, Zhiwei Chen, Yongfeng Yu, Ziming Li, Shun Lu

Get full text

Functional Characterization of a Novel SMR-Type Efflux Pump RanQ, Mediating Quaternary Ammonium Compound Resistance in <i>Riemerella anatipestifer</i> by Heng Quan, Xiaowei Gong, Qiwei Chen, Fuying Zheng, Yongfeng Yu, Donghui Liu, Wenhui Wang, Yuefeng Chu

Get full text

Comprehensive analysis of mutations in NSCLC patients in a real-world setting by Xinghao Ai, Yongfeng Yu, Jun Zhao, Wang Sheng, Jing Bai, Zaiwen Fan, Xuemei Liu, Wenxiang Ji, Rongrong Chen, Shun Lu

Get full text

Circulating tumour DNA biomarkers in savolitinib-treated patients with non-small cell lung cancer harbouring exon 14 skipping alterations: a analysis of a pivotal phase 2 study by Yongfeng Yu, Yongxin Ren, Jian Fang, Lejie Cao, Zongan Liang, Qisen Guo, Sen Han, Zimei Ji, Ye Wang, Yulan Sun, Yuan Chen, Xingya Li, Hua Xu, Jianying Zhou, Liyan Jiang, Ying Cheng, Zhigang Han, Jianhua Shi, Gongyan Chen, Rui Ma, Yun Fan, Sanyuan Sun, Longxian Jiao, Xiaoyun Jia, Linfang Wang, Puhan Lu, Qian Xu, Xian Luo, Weiguo Su, Shun Lu

Get full text

Homologous recombination deficiency (HRD) can predict the therapeutic outcomes of immuno-neoadjuvant therapy in NSCLC patients by Zhen Zhou, Zhengping Ding, Jie Yuan, Shengping Shen, Hong Jian, Qiang Tan, Yunhai Yang, Zhiwei Chen, Qingquan Luo, Xinghua Cheng, Yongfeng Yu, Xiaomin Niu, Liqiang Qian, Xiaoke Chen, Linping Gu, Ruijun Liu, Shenglin Ma, Jia Huang, Tianxiang Chen, Ziming Li, Wenxiang Ji, Liwei Song, Lan Shen, Long Jiang, Zicheng Yu, Chao Zhang, Zaixian Tai, Changxi Wang, Rongrong Chen, David P. Carbone, Xuefeng Xia, Shun Lu

Get full text

Gumarontinib in patients with non-small-cell lung cancer harbouring MET exon 14 skipping mutations: a multicentre, single-arm, open-label, phase 1b/2 trialResearch in context by Yongfeng Yu, Jianya Zhou, Xingya Li, Koichi Goto, Xuhong Min, Kazumi Nishino, Jiuwei Cui, Lin Wu, Jun Sakakibara, Yongqian Shu, Xiaorong Dong, Lu Li, Yasuto Yoneshima, Chengzhi Zhou, Xiaoling Li, Yiping Zhang, Dingzhi Huang, Aimin Zang, Wei Zhang, Xiuwen Wang, Li Zhang, Chong Bai, Jian Fang, Lejie Cao, Yanqiu Zhao, Yan Yu, Meiqi Shi, Diansheng Zhong, Fugen Li, Meng Li, Qiuxia Wu, Jun Zhou, Minghui Sun, Shun Lu

Get full text